Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KLRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKailera Therapeutics completes $718.8M IPO at $16/share with full overallotment exercised
Filed April 20, 2026 · Period ending April 20, 2026 · ~1 min read
Key Changes
-
high
Company raised $718.8 million gross proceeds by selling 44.9 million shares at $16 per share, with underwriters exercising full overallotment option indicating strong investor demand.
Item 8.01: IPO Completion verify on EDGAR → -
high
Authorized 800 million common shares and 10 million preferred shares, establishing maximum issuable shares without additional stockholder approval.
Item 5.03: Certificate Amendment verify on EDGAR → -
medium
Adopted classified board with three-year staggered terms, requiring two-thirds supermajority vote to remove directors for cause only—standard anti-takeover provisions limiting stockholder control.
Item 5.03: Governance Changes verify on EDGAR → -
medium
Eliminated stockholder ability to act by written consent, requiring formal meetings for all votes—reduces stockholder flexibility to effect rapid changes.
Item 5.03: Written Consent verify on EDGAR →
Summary
Kailera Therapeutics successfully completed its initial public offering on April 20, 2026, raising $718.8 million before fees by selling nearly 45 million shares at $16 each. The underwriters' full exercise of their overallotment option signals robust institutional demand for this biotech debut. The capital provides substantial runway for the company's therapeutic development programs.
Concurrent with the IPO, Kailera implemented standard public-company governance structures including a classified board with staggered three-year terms and supermajority voting requirements for director removal.
These provisions, combined with elimination of written consent rights, create meaningful barriers to hostile takeovers or activist campaigns—protecting management stability but limiting stockholder power to force rapid changes. Retail investors should monitor the company's first quarterly earnings report and any updates on clinical trial progress to understand how the IPO proceeds are being deployed. The $16 IPO price establishes an initial valuation benchmark against which future performance will be measured.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Kailera filed amended certificate and bylaws upon IPO closing, authorizing 800M common shares and establishing classified board structure.
Added in current filing · verify on EDGAR →
On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.
The company completed its initial public offering on April 20, 2026, and simultaneously filed an amended certificate of incorporation with Delaware. This marks the company's transition to being publicly traded.
Added in current filing · verify on EDGAR →
establish a classified board of directors, divided into three classes, each of whose members will serve for staggered three-year terms
The company adopted a staggered board structure with three classes serving three-year terms. This is a common anti-takeover provision that makes it harder for activists or acquirers to gain control of the board quickly.
Added in current filing · verify on EDGAR →
provide that directors may be removed from office only for cause and only upon the affirmative vote of the holders of at least two-thirds of the Company’s capital stock entitled to vote thereon
Directors can only be removed for cause and require a two-thirds supermajority vote. Combined with the classified board, this significantly limits stockholder ability to change board composition.
Added in current filing · verify on EDGAR →
eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting
Stockholders can no longer act by written consent and must wait for formal meetings to vote on matters. This reduces stockholder flexibility and is another governance provision that protects management from rapid changes.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The gross proceeds to the Company from the IPO were $718.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
The company raised $718.8 million in gross proceeds from the IPO before fees and expenses. This capital infusion provides significant funding for the company's operations, though net proceeds will be lower after deducting underwriting fees and offering costs.
Event · Item 9.01 — Financial Statements and Exhibits
Kailera filed restated certificate of incorporation and amended bylaws with no material business impact disclosed.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Restated Certificate of Incorporation of Kailera Therapeutics, Inc.
The company filed a restated certificate of incorporation. This is a routine corporate governance filing that consolidates prior amendments into a single document. Without the exhibit content, no material changes to shareholder rights or corporate structure can be identified.
Added in current filing · verify on EDGAR →
Amended and Restated Bylaws of Kailera Therapeutics, Inc.
The company filed amended and restated bylaws. This is a routine corporate governance update that typically addresses procedural matters like meeting requirements, director qualifications, or officer duties. Without the exhibit content, no material governance changes can be identified.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify